Retatrutide (LY3437943) is Eli Lillys experimental triple-agonist drug that activates: GLP-1 (Glucagon-like peptide-1) reduces appetite and slows digestion GIP (Glucose-dependent insulinotropic peptide) enhances insulin sensitivity Glucagon receptor increases fat metabolism and energy expenditure In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction rivaling or even surpassing bariatric surgery outcomes
Athletes for recovery and muscle support: Boosts endurance and repair
Just makes my heart happy That is the best feeling. I got little goosebumps , so it was pretty special, Luka said
(2022) demonstrated Cerebrolysin's effects on Alzheimer's disease biomarkers in a randomized controlled trial, providing objective biological evidence for its neurotrophic activity (PMID: 36155516) Regulatory Validation: Approved for clinical use in over 40 countries for indications including stroke, traumatic brain injury, and dementia (though not FDA-approved in the United States) Dihexa: Preclinical Only, with Integrity Concerns Dihexa's evidence base is entirely preclinical and has faced significant scientific integrity challenges: Foundational Research: Wright et al
The answer is in the delivery
Animal and cell studies show shifts in enzymes that convert cholesterol to sex steroids, suggesting possible effects on estrogen and testosterone levels
